Why did solid Biosciences stock crash 31% lower on Tuesday?
Feb 16, 2022 · Precision BioSciences (DTIL) closed the most recent trading day at $4.82, moving -0.62% from the previous trading session. This change lagged the S&P 500's 0.09% gain on the day. Elsewhere, the ...
Should you buy solid Biosciences stock at $15?
Jan 24, 2022 · Even the best stock pickers will make plenty of bad investments. And there's no doubt that Precision BioSciences, Inc. (NASDAQ:DTIL) stock has had a really bad year.In that relatively short period ...
Is solid Biotech stock headed to $15?
Apr 04, 2022 · Precision BioSciences (NASDAQ:DTIL shareholders incur further losses as stock declines 23% this week, taking one-year losses to 65%. finance.yahoo.com - January 24 at 8:12 AM. Precision Biosciences Inc Shares Close in on 52-Week Low - Market Mover. nasdaq.com - January 14 at 5:40 PM.
Is Precision BioSciences a good investment?
Precision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Who owns Precision BioSciences?
The largest shareholder is venBio Global Strategic Fund, which owns about 11 percent of company shares.Mar 28, 2019
Are Precision BioSciences public?
This is an initial public offering of shares of common stock by Precision BioSciences, Inc. We are offering shares of our common stock. The initial public offering price is expected to be between $ and $ per share.
When did Precision BioSciences go public?
March 28, 2019The shares commenced trading on the Nasdaq Global Select Market under the ticker symbol “DTIL” on Thursday, March 28, 2019.Apr 1, 2019
Where is Precision BioSciences located?
Durham, North CarolinaPrecision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com.
What Bioscience means?
noun. any science that deals with the biological aspects of living organisms.
Is DTIL a buy?
In short, this is how much a company is worth....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.93%2Buy18.44%3Hold9.99%4Sell5.61%2 more rows
What does beam therapeutics do?
Beam is pioneering the use of base editing — a potential new class of precision genetic medicines — with a vision of providing life-long cures to patients suffering from serious diseases.
Precision BioSciences provided an expanded update from its first clinical asset. Investors weren't impressed
What happened
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.
So what
Shares of Precision BioSciences ( NASDAQ:DTIL) fell as much as 51.4% today after the company announced updated data from its lead drug candidate at the annual meeting of the American Society of Hematology (ASH).
Now what
PBCAR0191 is a cellular medicine based on chimeric antigen receptor (CAR) T cells. Precision BioSciences used its proprietary ARCUS gene editing system to engineer the T cells to home in on CD19 antigens expressed by cancerous white blood cells.
Investors appear to be skeptical about the biotech's latest clinical update
Investors simply have to remain patient with Precision BioSciences. If the next data update from the higher dose demonstrates a continuation in dose-dependent biomarkers and maintains an acceptable safety profile, then the gene editing stock could bounce back.
What happened
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
So what
Shares of Solid Biosciences ( NASDAQ:SLDB) had crashed 31% lower as of 11:15 a.m. EDT on Tuesday. The company announced interim results from a phase 1/2 study of its gene therapy candidate SGT-001 in treating Duchenne muscular dystrophy (DMD) after the market close on Monday.
Now what
It's obvious that investors aren't convinced that Solid Biosciences has a winner on its hands with SGT-001, but the biotech's interim results did look pretty good.
Why does SEC recording make the ENVB stock decrease?
Solid Biosciences will continue to dose patients in its phase 1/2 study of SGT-001. The company plans to report 90-day biopsy data from these additional patients in the second half of this year.
How Enveric Biosciences has diluted the stock?
Enveric Biosciences (ENVB) is a creative biotechnology organization creating cutting-edge emotional well-being and oncology medicines and clinical disclosure stage, utilizing hallucinogenic determined particles for the psyche and manufactured cannabinoids for the body.
